{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:50:17Z","timestamp":1784098217578,"version":"3.55.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009294","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000}}],"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPPGH5342"],"award-info":[{"award-number":["OPPGH5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite <jats:italic>Wuchereria bancrofti<\/jats:italic> from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with <jats:italic>Brugia timori<\/jats:italic> infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with <jats:italic>B<\/jats:italic>. <jats:italic>timori<\/jats:italic> Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 subjects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant\u2019s home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25\/28, 89% vs. 8\/27, 30%, P &lt; 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing <jats:italic>B<\/jats:italic>. <jats:italic>timori<\/jats:italic> Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis.<\/jats:p>\n<jats:p><jats:bold>Trial Registration:<\/jats:bold> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02899936?term=NCT02899936&amp;draw=2&amp;rank=1\" xlink:type=\"simple\">NCT02899936<\/jats:ext-link>.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009294","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T17:40:09Z","timestamp":1617039609000},"page":"e0009294","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia"],"prefix":"10.1371","volume":"15","author":[{"given":"Taniawati","family":"Supali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenny","family":"Djuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-2443","authenticated-orcid":true,"given":"Michael","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Iskandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat","family":"Alfian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roospita","family":"Maylasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Destani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriani","family":"Lomiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominikus","family":"Minggu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-2367","authenticated-orcid":true,"given":"Daphne","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-6603","authenticated-orcid":true,"given":"Joshua","family":"Bogus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3824","authenticated-orcid":true,"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-3417","authenticated-orcid":true,"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"4","key":"pntd.0009294.ref001","doi-asserted-by":"crossref","first-page":"e0005321","DOI":"10.1371\/journal.pntd.0005321","article-title":"The first \"London Declaration\": The Commonwealth and its neglected tropical diseases","volume":"11","author":"PJ Hotez","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009294.ref002","article-title":"The London Declaration on Neglected Tropical Diseases: 5 years on","author":"DH Molyneux","year":"2017","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009294.ref003","article-title":"Transforming our world: the 2030 Agenda for Sustainable Development.","author":"Nations United","year":"2015","journal-title":"United Nations General Assembly"},{"key":"pntd.0009294.ref004","first-page":"457","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2018","volume":"94","author":"WHO","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"key":"pntd.0009294.ref005","article-title":"Elimination of lymphatic Filariasis as a public health problem","author":"World, Health, Assembly","year":"1997"},{"issue":"43","key":"pntd.0009294.ref006","first-page":"509","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2019","volume":"95","author":"WHO","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"pntd.0009294.ref007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0035-9203(84)90161-5","article-title":"Filariasis in Indonesia: clinical manifestations and basic concepts of treatment and control","volume":"78","author":"F Partono","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pntd.0009294.ref008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-308X(10)72008-X","article-title":"Elimination of lymphatic filariasis in Southeast Asia.","volume":"72","author":"M Sudomo","year":"2010","journal-title":"Adv Parasitol"},{"issue":"21","key":"pntd.0009294.ref009","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1001\/jama.1988.03720210040026","article-title":"Ivermectin for the treatment of Wuchereria bancrofti filariasis. Efficacy and adverse reactions","volume":"259","author":"V Kumaraswami","year":"1988","journal-title":"JAMA"},{"issue":"6","key":"pntd.0009294.ref010","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bull World Health Organ"},{"issue":"19","key":"pntd.0009294.ref011","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pntd.0009294.ref012","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pntd.0009294.ref013","doi-asserted-by":"crossref","first-page":"e2586","DOI":"10.1371\/journal.pntd.0002586","article-title":"Impact of six rounds of mass drug administration on Brugian filariasis and soil-transmitted helminth infections in eastern Indonesia","volume":"7","author":"T Supali","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0009294.ref014","doi-asserted-by":"crossref","first-page":"e0008301","DOI":"10.1371\/journal.pntd.0008301","article-title":"Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis","volume":"14","author":"CR Burgert-Brucker","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0009294.ref015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-3156.2002.00921.x","article-title":"Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae","volume":"7","author":"T Supali","year":"2002","journal-title":"Trop Med Int Health"},{"issue":"6","key":"pntd.0009294.ref016","doi-asserted-by":"crossref","first-page":"e1002839","DOI":"10.1371\/journal.pmed.1002839","article-title":"The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study","volume":"16","author":"GJ Weil","year":"2019","journal-title":"PLoS Med"},{"key":"pntd.0009294.ref017","unstructured":"Services USDoHaH. Common terminology criteria for adverse events (CTCAE) 2009 [cited 2018 8 June]. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"pntd.0009294.ref018","author":"CRRS","year":"2016"},{"issue":"4","key":"pntd.0009294.ref019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/2229-3485.167101","article-title":"Clinical Data Acquisition Standards Harmonization importance and benefits in clinical data management","volume":"6","author":"JR Gaddale","year":"2015","journal-title":"Perspect Clin Res"},{"issue":"4","key":"pntd.0009294.ref020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4269\/ajtmh.1993.48.591","article-title":"Treatment of subperiodic Brugia malayi infection with a single dose of ivermectin","volume":"48","author":"JW Mak","year":"1993","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0009294.ref021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00034983.1992.11812664","article-title":"Jalajakumari. Ivermectin for the treatment of periodic malayan filariasis: a study of efficacy and side effects following a single oral dose and retreatment at six months","volume":"86","author":"RK Shenoy","year":"1992","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0009294.ref022","article-title":"Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Cote d\u2019Ivoire: an open-label, randomized, controlled trial","author":"CM Bjerum","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0009294.ref023","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.Epub","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009294","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T21:01:08Z","timestamp":1617915668000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009294"}},"subtitle":[],"editor":[{"given":"Marc P.","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009294","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0009294","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}